Bristol Myers Squibb's admilparant met the Phase III ALOFT-IPF primary endpoint, showing significant FVC gains in pulmonary ...
EU application is back under EMA review for EGFR-mutated NSCLC. Find out what this resubmission means for patients today.
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
A JAMA Phase III trial finds nicotinamide riboside worsens outcomes vs placebo in early Parkinson's. Read the full NOPARK ...
FDA approves Hovilpri (pritelivir) for herpes lesions resistant to acyclovir, valacyclovir, or famciclovir in ...
FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means ...
Chai Discovery and GSK announce a collaboration giving GSK access to protein folding and design AI models after wet-lab ...
AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share deal to gain RL-007 (inidascamine), a pro-cognitive candidate. Read full details.
Paris-based Rivercell raises $25M seed led by HV to build its AI Virtual Cell model that predicts how human cells respond to drugs. Explore how it works.
The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.
Viatris agrees to acquire Pacira BioSciences in a $1.65B all-cash deal at $36.50 per share. Read how this non-opioid pain ...
Biohaven grants Ono Pharma exclusive rights to its MoDE pan-IgG degrader portfolio in Japan and Asia, with $80M upfront. Read the full deal details now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results